Pfizer receives FDA backing over Prevnar 13

Pfizer has been granted approval by the Food and Drug Administration (FDA) for Prevnar 13, its treatment for invasive pneumococcal disease among children and infants.

The pharmaceutical company saw its application of the vaccine, which is also indicated for use against otitis media, ratified by the regulator following strong performance in clinical trials.

In connection with this approval, the company has also agreed to perform further studies into the vaccine to evaluate its effectiveness against the diseases.

The FDA ruling was welcomed by Geno Germano, president and general manager of Pfizer’s specialty care business unit, who described the drug as an “important priority” for the company.

He added: “This approval is a significant milestone for Pfizer and yet another expression of our mission to improve health and well-being at every stage of life.”

Earlier this week, the company revealed plans to collaborate with Lilly and Merck Sharpe and Dohme on a new cancer research initiative centred around the Asian region.